Sorafenib Tosylate

Sorafenib Tosylate（CAS 475207-59-1）的公开数据库记录，列此仅供独立核对。

危险化学品分类与危害说明

这个物质在各数据库里的编号

数据库记载的用途

• Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
• Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;
• Sorafenib tosylate is approved to treat:
• • Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery.
• • Renal cell carcinoma (a type of kidney cancer) that is advanced.
• • Thyroid cancer in certain patients whose cancer has gotten worse, has come back, or has spread to other parts of the body and did not respond to treatment with radioactive iodine.

它在各数据库里的别名

Sorafenib tosylate; 475207-59-1; Nexavar; Sorafenib tosilate; DTXSID9047839; BAY 54-9085; 5T62Q3B36J; NSC724772; BAY-54-9085; BAY 43-9006 tosylate; DTXCID9027817; CHEBI:50928; RefChem:57444; 641-758-8; Sorafenib tosylate [USAN]; MFCD08235032

计算机算出的分子描述符

数据库摘要

Sorafenib Tosylate · CAS 475207-59-1 · C28H24ClF3N4O6S. UNII 5T62Q3B36J.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。